Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 6/2006

01-06-2006

Expression of Interleukin 11 and Its Receptor and Their Prognostic Value in Human Breast Cancer

Authors: Satheesha Hanavadi, MS, FRCS, Tracey A. Martin, PhD, Gareth Watkins, HND, Robert E. Mansel, MS, FRCS, Wen G. Jiang, MB MCh, MD

Published in: Annals of Surgical Oncology | Issue 6/2006

Login to get access

Abstract

Background

Recent experimental evidence has shown a potential role of interleukin (IL)-11 and its receptor in breast cancer development and progression. However, there is little clinical information to support this hypothesis. We examined the expression of IL-11 and its receptor in primary breast cancer tissue samples and correlated their level of expression with the clinical outcome.

Methods

Primary breast cancer samples (n = 109) and matched background tissue obtained from patients in the cohort (n = 33) were processed for frozen section and RNA extraction. Frozen sections from matched tissues were immunostained with IL-11 and IL-11 receptor antibodies. Staining intensity was analyzed by computer image analysis. RNA was reverse-transcribed and quantified before analysis by quantitative polymerase chain reaction. Results were expressed as the number of transcripts (standardized by β-actin). The data were compared with the clinical outcome of the disease.

Results

The intensity of staining for both IL-11 and the IL-11 receptor was distinctly high in tumor samples (P < .01). The transcript level of IL-11 was significantly higher in node-positive tumor samples compared with node-negative samples (P = .02). Tumors with a poor prognostic index and poor histological grade showed a higher level of IL-11. A higher level of IL-11 was linked to poorer survival with Kaplan-Meier survival analysis.

Conclusions

IL-11 can be a predictor of poor prognosis in human breast cancer.
Literature
1.
Pisani P, Parkin DM, Ferlay J. Estimates of worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer 1993; 55:891–903PubMed
2.
Van ‘t Veer LJ, Dai H, Van De Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415:530–6CrossRefPubMed
3.
Kang Y, Seigel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003; 3:537–49CrossRefPubMed
4.
Crichton MB, Nichols JE, Zhao Y, Bulun SE, Simpson ER. Expression of transcript of interleukin-6 and related cytokines by human breast tumours, breast cancer cells and adipose stromal cells. Mol Cell Endocrinol 1996; 118:215–20CrossRefPubMed
5.
Douglas AM, Goss GA, Sutherland RL, et al. Expression and function of members of the cytokine receptor superfamily on breast cancer cells. Oncogene 1997; 14:661–9CrossRefPubMed
6.
Morinaga Y, Fujita N, Ohishi K, Zhang Y, Tsuruo T. Suppression of interleukin-11 mediated bone resorption by cyclooxygenase inhibitor. J Cell Physiol 1998; 175:247–54CrossRefPubMed
7.
Lacroix M, Siwek B, Marie PJ, Body JJ. Production and regulation of interleukin-11 by breast cancer cells. Cancer Lett 1998; 127:29–35CrossRefPubMed
8.
Manolagas SC, Jilka RL. Bone marrow, cytokines and remodelling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995; 332:305–11CrossRefPubMed
9.
10.
Arguello F, Baggs RB, Frantz CN. A murine model of experimental metastasis to bone and bone marrow. Cancer Res 1988; 48:6876–81PubMed
11.
Morgan H, Tumber A, Hill PA. Breast cancer cells induce osteoclast formation by stimulating host IL-11 production and down regulating granulocyte/macrophage colony-stimulating factor. Int J Cancer 2004; 109:653–60CrossRefPubMed
12.
Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham prognostic index in primary breast cancer. Breast Cancer Res Treat 1992; 22:207–19CrossRefPubMed
13.
Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. 1. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19:403–10PubMed
14.
Chomczynske P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162:156–9
15.
Jiang WG, Watkins G, Lane J, et al. Prognostic value of Rho family and rho-GDIs in breast cancer. Clin Cancer Res 2003; 9:6432–40PubMed
16.
Martin TA, Goyal A, Watkins G, Jiang WG. Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer. Ann Surg Oncol 2005; 12:1–9CrossRef
17.
Davies G, Jiang WG, Mason MD. Cell–cell adhesion and signaling intermediates in human prostate cancer. J Urol 2000; 163:985–92CrossRefPubMed
18.
King JAC, Ofori-Acquash AF, Stevens T, Al-Mehdi AB, Fodstad O, Jiang WG. Prognostic value of ALCAM in human breast cancer. Breast Cancer Res 2004; 6:478–87CrossRef
19.
Paul SR, Bennett F, Calvotti JA, et al. Molecular cloning of a cDNA encoding interleukin-11, a stromal cell-derived lymphopoietic and hematopoietic cytokine. Proc Natl Acad Sci USA 1990; 87:7512–6PubMed
20.
Du X, Williams DA. Interleukin-11: review of molecular, cell biology and clinical use. Blood 1997; 89:3897–908PubMed
21.
Sotiriou C, Lacroix M, Lespagnard L, Larsimont D, Paesmans M, Body JJ. Interleukin-6 and -11 expression in primary breast cancer and subsequent development of bone metastasis. Cancer Lett 2001; 169:87–95CrossRefPubMed
Metadata
Title
Expression of Interleukin 11 and Its Receptor and Their Prognostic Value in Human Breast Cancer
Authors
Satheesha Hanavadi, MS, FRCS
Tracey A. Martin, PhD
Gareth Watkins, HND
Robert E. Mansel, MS, FRCS
Wen G. Jiang, MB MCh, MD
Publication date
01-06-2006
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 6/2006
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/ASO.2006.05.028

Other articles of this Issue 6/2006

Annals of Surgical Oncology 6/2006 Go to the issue

OriginalPaper

The Surgeon-Patient Interaction in Older Women With Breast Cancer: What Are the Determinants of a Helpful Discussion?

Educational Review

Colorectal Cancer Screening and Surveillance: Current Standards and Future Trends

OriginalPaper

Prognostic Significance of Epidermal Growth Factor Receptor Expression in Colon Cancer Patients Undergoing Curative Surgery

OriginalPaper

Consensus Statement on Surgery Journal Authorship – 2006

OriginalPaper

Satisfaction With Care: An Independent Outcome Measure in Surgical Oncology

Editorial

Completion Lymphadenectomy for Melanoma Patients With a Positive Sentinel Node Biopsy Remains Standard of Care